Company profile

Ticker
OMI
Exchange
CEO
Edward A. Pesicka
Employees
Incorporated in
Location
Fiscal year end
Former names
O&m Holding Inc, Owens & Minor Inc
SEC CIK
IRS number
541701843

OMI stock data

(
)

Calendar

6 May 20
14 Jul 20
31 Dec 20

News

Company financial data Financial data

Quarter (USD) Mar 20 Dec 19 Sep 19 Jun 19
Revenue 2.12B 1.87B 2.4B 2.48B
Net income -11.32M -39.02M 1.22M -10.48M
Diluted EPS -0.19 -0.64 0.02 -0.18
Net profit margin -0.53% -2.09% 0.05% -0.42%
Operating income 10.76M 17M 25.31M 16.14M
Net change in cash 25.29M -29.77M 5.46M 16.1M
Cash on hand 92.32M 67.03M 96.8M 91.34M
Cost of revenue 1.85B 1.83B 2.04B 2.12B
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 9.21B 9.42B 9.32B 9.72B
Net income -62.37M -437.01M 72.79M 108.79M
Diluted EPS -1.03 -7.28 1.2 1.76
Net profit margin -0.68% -4.64% 0.78% 1.12%
Operating income 73.15M -352.35M 89.25M 199.6M
Net change in cash 722K -38.21M -80.97M 24.47M
Cash on hand 67.03M 66.31M 104.52M 185.49M
Cost of revenue 8.08B 8.35B 8.15B 8.54B

Financial data from company earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
30 Jun 20 Mark F Mcgettrick Phantom Stock Common Stock Grant Aquire A No 7.62 28 213.36 103,100
30 Jun 20 Moore Eddie N JR Phantom Stock Common Stock Grant Aquire A No 7.62 9 68.58 28,808
3 Jun 20 Zacur Mark P Common Stock Payment of exercise Dispose F No 7.64 4,808 36.73K 93,468
1 Jun 20 Mark F Mcgettrick Phantom Stock Common Stock Grant Aquire A No 7.84 4,624 36.25K 103,072
1 Jun 20 Robert J Henkel Phantom Stock Common Stock Grant Aquire A No 0 996 0 35,934
87.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 184 181 +1.7%
Opened positions 36 29 +24.1%
Closed positions 33 24 +37.5%
Increased positions 61 63 -3.2%
Reduced positions 52 55 -5.5%
13F shares
Current Prev Q Change
Total value 2.52B 1.13B +122.8%
Total shares 55.09M 56.94M -3.3%
Total puts 92.3K 315.2K -70.7%
Total calls 629.3K 678.1K -7.2%
Total put/call ratio 0.1 0.5 -68.4%
Largest owners
Shares Value Change
BLK BlackRock 9.66M $88.4M -3.5%
Vanguard 5.18M $47.42M -2.1%
Dimensional Fund Advisors 4.95M $45.32M -1.8%
Renaissance Technologies 3.03M $27.74M +21.6%
JPM JPMorgan Chase & Co. 2.72M $24.89M -47.3%
STT State Street 2.65M $24.25M -2.3%
Royce & Associates 2.05M $18.77M -3.9%
LSV Asset Management 1.81M $16.59M +5.2%
FRLG Goldman Sachs 1.69M $15.43M +393.5%
IVZ Invesco 1.21M $11.11M -13.5%
Largest transactions
Shares Bought/sold Change
JPM JPMorgan Chase & Co. 2.72M -2.44M -47.3%
FRLG Goldman Sachs 1.69M +1.34M +393.5%
Clough Capital Partners L P 0 -1.24M EXIT
PUK Prudential 0 -784.5K EXIT
MS^L Morgan Stanley 991.42K +605.25K +156.7%
Renaissance Technologies 3.03M +538.25K +21.6%
BLK BlackRock 9.66M -348.88K -3.5%
Engineers Gate Manager 0 -327.62K EXIT
Arrowstreet Capital, Limited Partnership 636.81K +326.81K +105.4%
Oxford Asset Management 0 -320.76K EXIT

Financial report summary

?
Risks
  • We face competition and accelerating pricing pressure.
  • We have significant concentration in and dependence on certain healthcare provider customers and Group Purchasing Organizations.
  • Our operating income is dependent on certain significant domestic suppliers.
  • Our results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a customer that has a substantial amount owed to us.
  • Changing conditions in the United States healthcare industry may impact our results of operations.
  • We may not be able to generate sufficient cash to service our debt and other obligations.
  • Our credit facilities and our existing notes have restrictive covenants that could limit our financial flexibility.
  • An interruption in the ability of our business to manufacture products may have a material adverse effect on our business.
  • An inability to obtain key components, raw materials or manufactured products from third parties may have a material adverse effect on our Global Products segment.
  • We may incur product liability losses, litigation liability, product recalls, safety alerts or regulatory action associated with the products that we source, assemble, manufacture and sell which can be costly and disruptive to our business.
  • We must obtain clearance or approval from the appropriate regulatory authorities prior to introducing a new product or a modification to an existing product. The regulatory clearance process may result in substantial costs, delays and limitations on the types and uses of products we can bring to market, any of which could have a material adverse effect on our business.
  • Our inability to adequately integrate acquisitions could have a material adverse effect on our operations.
  • Our Global Products segment is exposed to price fluctuations of key commodities, which may negatively impact our results of operations.
  • Our business and operations depend on the proper functioning of critical facilities, supply chain and distribution networks.
  • Our investment in Fusion5 may continue to incur losses.
  • We are subject to stringent regulatory and licensing requirements.
  • Compliance with the terms and conditions of Byram’s Corporate Integrity Agreement requires significant resources and, if we fail to comply, we could be subject to penalties or excluded from participation in government healthcare programs, which could seriously harm our results of operations, liquidity and financial condition.
  • General economic conditions may adversely affect demand for our products and services.
  • We operate within the European Union and therefore may be affected by the United Kingdom's withdrawal from the European Union.
  • Our continued success is substantially dependent on positive perceptions of our reputation.
  • We may experience competition from third-party online commerce sites.
  • Audits by tax authorities could result in additional tax payments for prior periods, and tax legislation could materially adversely affect our financial results and tax liabilities.
  • Recent significant changes to our executive leadership team and any future loss of members of such team, and the resulting management transitions might harm our future operating results.
  • Our goodwill may become impaired, which would require us to record a significant charge to earnings in accordance with generally accepted accounting principles.
  • The market price for our common stock may be highly volatile.
  • We cannot assure you that the proposed Movianto sale will be completed.
  • We and the Movianto business will be subject to business uncertainties while the sale is pending that could adversely affect our business and the Movianto business.
Management Discussion
  • Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
  • Owens & Minor, Inc., along with its subsidiaries, (we, us, or our) is a leading global healthcare solutions company. On January 16, 2020, we announced our intention to sell our European logistics business, Movianto, to EHDH Holding Group (EHDH), a privately held French company. The divestiture is intended to provide us with a greater ability to focus on and invest in our differentiated products, services and U.S. distribution businesses. See Note 3, “Discontinued Operations,” of the Notes to Consolidated Financial Statements for further information. Unless otherwise indicated, the following information relates to continuing operations.
  • Net loss per diluted share was $(0.15) for the three months ended March 31, 2020, as compared to $(0.18) for same period of 2019. Global Solutions segment operating income was $7.7 million for the three months ended March 31, 2020, compared to $21.6 million for 2019. The declines were a result of lower revenues and continued pressure on distribution margins as compared to prior year. Global Products segment operating income was $18.6 million for the three months ended March 31, 2020, compared to $7.7 million for the three months ended March 31, 2019, largely reflecting an increase in revenues from higher market demand for personal protective equipment in the first quarter of 2020 compared to 2019.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Good
New words: achieve, added, Additionally, addressed, Aid, alter, announced, apparel, ASC, avoid, aware, billion, breakage, broader, carryback, cease, center, certainty, challenging, cleaning, closure, commercial, compel, compete, consideration, create, criteria, critical, cybersecurity, Defense, delay, Department, description, differentiated, difficult, disruption, divestiture, divided, document, DPA, duration, dynamic, EHDH, employee, equal, essential, estate, exacerbate, exceed, expansion, expedite, expedited, export, face, facial, Facilitation, factor, force, found, Framework, freight, French, functioning, good, governmental, greater, Group, grow, half, heading, Holding, import, important, impose, imposing, imposition, inability, influence, infrastructure, inhibit, instituting, intention, Interbank, introduce, IRS, led, length, LIBOR, Likewise, line, LLC, local, locally, London, lose, mandated, manmade, mentioned, met, modified, Movianto, negatively, NOL, nominal, Offered, outbreak, outsourced, pandemic, paydown, people, PPE, produce, promote, proper, protect, protection, protective, public, purpose, quarantine, rapidly, real, recommended, recovery, redemption, refund, remote, remotely, reorganization, reputation, respirator, safety, scale, sea, sector, securitization, shift, situation, small, speed, spending, stopped, strain, subsidizing, Subtopic, suffer, temporary, tranche, transmission, travel, Treasury, unable, unintended, unpredictability, upgrading, voice, wholly, workforce, world, yield
Removed: acquired, acute, Affordable, allocate, amortizing, approach, assert, assessed, assigned, assist, assumed, authorization, authorized, carefully, closing, commenced, commencement, comparable, comparative, comparing, comparison, compensation, consist, consistent, continuum, core, deductible, depending, depreciable, determinable, determining, development, disclosing, effected, enacted, enactment, enhanced, EPS, established, evaluated, exact, executed, exemption, exercise, expedient, expiring, finance, forecasted, forward, frequency, historic, historical, human, identification, implicit, incentive, Infection, inherent, initial, integration, intellectual, internally, Issuer, July, layered, leasehold, life, marketing, multiple, noted, number, obtained, October, Overview, owing, package, par, permanent, pertaining, planned, planning, practical, preceding, predictable, presence, prevention, procurement, prohibiting, quality, ranging, readily, realize, recognize, recognizing, recording, reinvestment, relate, renewal, Rent, represent, research, residual, restated, restrictive, retained, return, section, select, separate, similarly, sufficiency, superior, supplemental, sustained, Targeted, terminate, title, titled, transfer, transitional, typically, understanding, undistributed, Unregistered, vacated, valuation, warehouse, weighted, welfare